TheraNest vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management and therapy notes software for mental health practitioners, acquired by Therapy Brands. Serves solo practices, group practices, and agencies.
About
TheraNest is a cloud-based practice management and clinical documentation platform for mental health practitioners, including therapists, social workers, counselors, and psychologists. Originally founded as an independent company, TheraNest was acquired by Therapy Brands, a technology roll-up focused on behavioral health software, which also owns Therapy Brands, ICANotes, and other mental health practice management systems. TheraNest serves a broad range of practice types from solo practitioners to large group practices and nonprofit agencies.\n\nThe platform provides scheduling, billing, telehealth, clinical notes, treatment planning, and client portal functionality in a unified interface. TheraNest is particularly recognized for its affordability and straightforward pricing model, which has made it a popular choice for practices with tight administrative budgets and those serving Medicaid populations. The product supports both individual and group therapy documentation workflows, including co-signature and supervision features relevant to practices employing pre-licensed associates.\n\nAs part of the Therapy Brands portfolio, TheraNest benefits from shared infrastructure investment and cross-selling opportunities, while maintaining its standalone brand and product identity. The mental health EHR market is competitive, with SimplePractice, TherapyNotes, and Jane App also vying for the small-to-mid-size practice segment. TheraNest's acquisition has allowed it to invest in product development while leveraging Therapy Brands' broader customer relationships and compliance infrastructure.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.